GLOBAL MARKETS: Barclays CEO in hot water over whistleblower
And one of Europe’s last makers of generic drugs is bought by Bain and Cinven
Stada Arzneimittel agreed to sell itself to Bain Capital and Cinven for €5.3bn, giving the private equity firms control of one of the last independent generic-drug businesses in Europe after a long-fought takeover contest. Bain Capital and Cinven will offer €65.28 plus a dividend of €0.72 per Stada share, the German drug maker said. Barclays CEO Jes Staley faces probe, bonus cut Barclays CEO Jes Staley will be reprimanded and the bank will cut his pay as regulators begin to investigate how he tried to unmask a whistleblower last year. The UK’s Financial Conduct Authority is investigating both Staley’s individual conduct relating to the complaint and the bank’s responsibilities and controls in connection with whistleblowing, the bank said on Monday. Staley had admitted his error and formally apologised to the board, Barclays said. Bloomberg
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.